Discounted Cash Flow
Krystal Biotech, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-1.1m | $-1.3m | — | $-1.31 |
| 2017 | — | $-7.9m (-588.7%) | $-4.1m (-209.2%) | — | $-1.48 (-13.0%) |
| 2018 | — | $-10.9m (-37.5%) | $-11.7m (-184.9%) | — | $-0.97 (34.5%) |
| 2019 | — | $-19.1m (-75.3%) | $-25.1m (-115.0%) | — | $-1.20 (-23.7%) |
| 2020 | — | $-32.2m (-68.5%) | $-40.9m (-63.0%) | — | $-1.71 (-42.5%) |
| 2021 | $0 | $-69.6m (-116.3%) | $-116.3m (-184.1%) | — | $-3.13 (-83.0%) |
| 2022 | $0 | $-140.0m (-101.2%) | $-153.5m (-32.1%) | — | $-5.49 (-75.4%) |
| 2023 | $50.7m | $10.9m (107.8%) | $-100.6m (34.5%) | 21.6% | $0.40 (107.3%) |
| 2024 | $290.5m (473.0%) | $89.2m (715.6%) | $119.2m (218.5%) | 30.7% (42.3%) | $3.12 (680.0%) |
| 2025 | $389.1m (33.9%) | $204.8m (129.7%) | $188.9m (58.5%) | 52.6% (71.5%) | $7.08 (126.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.